Clinical and Experimental Pharmacology and Physiology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis
CONCLUSIONS: In summary, these data suggest that TAN IIA can reduce SSc-related skin fibrosis by modulating the TGF-β/Smad and MAPK/ERK signalling pathways. More importantly, our results imply that TAN IIA can directly act on the skin fibroblasts of SSc, therefore, inhibiting fibrosis.PMID:38037494 | DOI:10.1111/1440-1681.13834 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - December 1, 2023 Category: Drugs & Pharmacology Authors: Ying Jiang Feifei Hu Ming Li Qiao Li Source Type: research